Pixurvi® is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).
Rapid Review
| Commenced | Completed | Outcome |
| 10/02/2015 | 20/03/2015 | Full Pharmacoeconomic Evaluation Not Recommended |